

MARKET REPORT



Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, "Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additional Details

Publisher : Global Data

Reference : GDHC4814CTIDB

Number of Pages : 1556

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

- Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Global Data Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 32
Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 32
Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 32
Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting 33
Jan 16, 2018: Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma 33
Jan 08, 2018: Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma 34
Jan 02, 2018: Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma 34
Dec 21, 2017: BioLineRx Announces Initiation of Phase III GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients 35
Dec 18, 2017: Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma 35
Dec 12, 2017: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible 36
Dec 12, 2017: Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies 36
Dec 12, 2017: Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple 37
Dec 11, 2017: PharmaMar shows new data on plitidepsin for the treatment of multiple myeloma at ASH annual meeting 38
Dec 11, 2017: TeneoBio's Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology 38
Dec 11, 2017: New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma 38
Dec 11, 2017: Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study 40
Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40
Dec 10, 2017: Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting 41
Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 42
Dec 07, 2017: Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342 42
Dec 07, 2017: Sanofi explores combination treatments for multiple myeloma in new late-stage trials 42
Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 43
Nov 29, 2017: Bristol-Myers Squibb to Present New Data on Multiple Myeloma Drug Elotuzumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 43
Nov 29, 2017: Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform 44
Clinical Trial Profile Snapshots 46
Appendix 1553
Abbreviations 1553
Definitions 1553
Research Methodology

List Of Tables in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

List of Tables

- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 8
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 22
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
- Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

List Of Figures, Charts and Diagrams in Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

List of Figures

- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
- Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
- Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
- Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
- Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
- Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
- Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

How to Buy...

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 [Report Updated: 28-02-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/211035>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.